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Abstract
Background: Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are the main cause for
hospitalisation. These hospitalisations result in a high pressure on hospital beds and high health care costs. Because
of the increasing prevalence of COPD this will only become worse. Hospital at home is one of the alternatives that
has been proved to be a safe alternative for hospitalisation in COPD. Most schemes are early assisted discharge
schemes with specialised respiratory nurses providing care at home. Whether this type of service is cost-effective
depends on the setting in which it is delivered and the way in which it is organised.
Methods/Design: GO AHEAD (Assessment Of Going Home under Early Assisted Discharge) is a 3-months,
randomised controlled, multi-centre clinical trial. Patients admitted to hospital for a COPD exacerbation are either
discharged on the fourth day of admission and further treated at home, or receive usual inpatient hospital care.
Home treatment is supervised by general nurses. Primary outcome is the effectiveness and cost effectiveness of an
early assisted discharge intervention in comparison with usual inpatient hospital care for patients hospitalised with
a COPD exacerbation. Secondary outcomes include effects on quality of life, primary informal caregiver burden and
patient and primary caregiver satisfaction. Additionally, a discrete choice experiment is performed to provide
insight in patient and informal caregiver preferences for different treatment characteristics. Measurements are
performed on the first day of admission and 3 days, 7 days, 1 month and 3 months thereafter. Ethical approval has
been obtained and the study has been registered.
Discussion: This article describes the study protocol of the GO AHEAD study. Early assisted discharge could be an
effective and cost-effective method to reduce length of hospital stay in the Netherlands which is beneficial for
patients and society. If effectiveness and cost-effectiveness can be proven, implementation in the Dutch health
care system should be considered.
Trial registration: Netherlands Trial Register NTR1129.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is a
chronic disease that is currently ranked as fourth major
cause of death globally [1]. Due to an aging population
and late effects of smoking, the prevalence of COPD
will increase in the following 20 years [2]. Projections
for the year 2030 indicate that COPD will be third
major cause of death, as a result of the projected
increase of tobacco use, especially among women and
low-and middle income countries [1]. COPD is charac-
terised by an airflow limitation which is not fully rever-
sible. Symptoms include sputum production, cough and
dyspnoea. These symptoms are chronic and progressive
over time [3].
Acute exacerbations of COPD can be defined as ‘an
event in the natural course of the disease characterized
by a change in a patients’ baseline dyspnoea, cough and/
or sputum production that is beyond the day-to-day var-
iations, is acute in onset, and may warrant a change in
regular medication in a patient with underlying COPD’
[3]. The exacerbation frequency is dependent on several
factors including disease severity and number of exacer-
bations in the previous year [4,5]. Although most
exacerbations are treated in the community [5], exacer-
bations are the main cause for hospitalisations in COPD
patients [5,6]. Studies have shown that exacerbations
and hospital admissions negatively influence patient out-
comes, by increasing lung function decline [5,6],
decreasing quality of life [7,8], increasing mortality [9]
and increasing readmission risk [8,10].
With a mean length of stay in the hospital of 9 days
[6,11] the large number of hospital admissions for exacer-
bations among COPD patients result in a high pressure on
scarce hospital beds and high health care costs, accounting
for up to 70% of total expenses for COPD [12,13]. Even
without intervention, hospital costs will rise as a result of
the increasing prevalence of COPD, especially among
women. To reduce health care costs, alternatives for hos-
pital treatment have been developed. One alternative that
has gained popularity in the last 15 years are hospital at
home schemes [14,15]. These schemes aim at reducing the
pressure on hospital beds and overall health care costs
without negatively influencing the patient outcomes and
increase patient satisfaction [16].
Hospital at home and early assisted discharge
Hospital at home is defined as “a service that provides
active treatment by health care professionals in the
patient’s home for a condition that otherwise would
require acute in-patient care, and always for a limited
time period”[17]. Hospital at home is also known as
‘home hospitalisation’ or ‘hospital in the home’. Depend-
ing on the target population of the scheme and the type
of care provided, schemes vary in organisational struc-
ture and may involve different professionals [17]. Hospi-
tal at home schemes can be divided in admission
avoidance schemes, (early) assisted or supported dis-
charge schemes and combined schemes. Depending on
who bears the financial and management responsibil-
ities, the schemes can further be divided in community
resourced or hospital resourced. Community resourced
schemes commonly built on the existing infrastructure
for care provision in the community, whereas hospital
resourced schemes work on an outreach basis and home
care is provided by hospital staff.
Hospital at home for COPD exacerbations
Hospital at home schemes for the treatment of COPD
exacerbations specifically, have been studied in several
randomised controlled trials [18-25] and various non-
randomised studies including observational studies
[26-31] and studies with retrospective analysis [32]. Stu-
dies were performed in the United Kingdom
[19,20,24-29,32], Ireland [30], Australia [23], Italy [18]
and Spain [21,22,31]. These studies showed that
approximately 25% of all patients with an acute exacer-
bation of COPD can be treated at home safely with no
negative effects on their health outcomes and with great
patient satisfaction [16]. These results triggered the wide
implementation of hospital at home schemes for COPD
exacerbations in the United Kingdom over the last 10
years [14,15]. In 2007, the British Thoracic Society
developed the Hospital-at-Home in Chronic Obstructive
Pulmonary Disease guideline providing a framework for
the development and adjustment of hospital at home
schemes [33].
Most hospital at home schemes active in the United
Kingdom are assisted discharge schemes, with specia-
lised respiratory nurses providing home care on an out-
patient basis [14,15]. However, it remains unknown
whether this is the most effective model for hospital at
home care. The use of generic community district
nurses or telephone monitoring might be an option that
increases the capacity of the hospital at home schemes
for COPD exacerbation. Supported by their positive
results, Davison et al. [28] suggest that the use of gen-
eric community nurses in hospital at home schemes
should be studied more intensively.
Hospital at home for COPD exacerbations initially
requiring hospital admission has also been the subject of
several cost or cost-effectiveness studies
[18,22,23,25,34-36]. Significant and substantial cost sav-
ings were found in Australia (€1200 per episode) [23],
Spain (€800) [22,35] and the United States (€1700) [37].
No significant cost savings were found for England and
Italy [36]. (Amounts were converted to Euros, using
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exchange rates of March 2010). All studies were per-
formed from a health care or payer perspective, meaning
that they recorded only costs in the health care sector
and not included costs of informal care. Although treat-
ing COPD exacerbations at home has the potential to
reduce costs, whether and the extent to which it does so
in the Netherlands is unknown. Apart from the exact
organisation of the hospital at home scheme, its health
economic impact depends heavily on national and local
treatment patterns, health care delivery structures, fund-
ing and reimbursement systems, absolute and relative
differences in unit costs of resource use and drug prices.
The limited transferability of cost-effectiveness results to
other settings stresses the need for setting-specific cost-
effectiveness studies.
This contribution presents the design of the GO
AHEAD trial (GO AHEAD is an acronym for Assess-
ment Of Going Home under Early Assisted Discharge).
In this Randomised Controlled Trial (RCT) patients
admitted to the hospital for an exacerbation of their
COPD are discharged early and monitored at home by
nurses.
Research questions
Our primary research question is: “What is the effective-
ness and cost-effectiveness of an early assisted discharge
intervention compared to hospital care as usual for
patients hospitalised with an exacerbation of their
COPD.” The primary measure of effectiveness will
expressed by the change in health status, measured by
the change in Clinical COPD Questionnaire (CCQ) [38]
scores between randomisation and day 7, while costs
include COPD-related health care costs, patients’ and
informal caregivers’ out-of-pocket costs and patients’
and informal caregivers’ costs of production loss.
The following secondary research questions will be
addressed:
1) What is the long-term effectiveness of early
assisted discharge compared to hospital care as
usual?
2) What is the difference in treatment failures
between the early assisted discharge scheme and
usual care in hospital?
Treatment failure in the intervention group is
defined as readmission before day 7 or death before
day 7. In the control group treatment failure is
defined as death before day 7 or clinical deteriora-
tion leading to prolongation of hospital stay after
day 7.
3) What is the effect of early assisted discharge on
readmission rates after discharge from hospital or
the early assisted discharge scheme, in comparison
with usual care in hospital?
4) What is the effect of early assisted discharge on
mortality after discharge from hospital or early
assisted discharge scheme, in comparison with usual
care in hospital?
5) What is the effect of early assisted discharge on
patients quality of life in comparison with usual care
in hospital?
6) What is the effect of early assisted discharge on
primary informal caregiver burden in comparison
with usual care in hospital?
7) How is patient and primary informal caregiver
satisfaction with the early assisted discharge scheme
compared with usual care in hospital?
Additionally a discrete choice experiment (DCE) is
performed in order to provide more insight in patient




The GO AHEAD study is a randomised controlled,
multi-centre trial comparing two management strategies
for patients admitted to the hospital for a COPD exacer-
bation. The intervention strategy is early assisted dis-
charge, which implies that patients are discharged early
from hospital with a package of home care. Recovery is
monitored while patients are further treated at home.
This management strategy is compared to usual hospital
care, where patients remain hospitalised and are moni-
tored in hospital. The total length of the active, super-
vised treatment phase for both groups is planned to be
seven days. The follow up period of the trial is three
months. Figure 1 gives a complete overview of the study
design. Main focus of the study is not only to perform
an effect evaluation, but also a cost evaluation and a dis-
crete choice experiment. This trial was approved by the
Medical Ethics Committee of the Catharina-hospital
Eindhoven, the Netherlands and this approval was
reconfirmed by the Medical Ethics Committees of the
other participating hospitals.
Setting and recruitment
Patients admitted to one of the participating hospitals
because of an exacerbation of their COPD, through
either the emergency and accident department or after
an unscheduled outpatient visit to the pulmonologist,
are screened for eligibility. Patients are assessed for elig-
ibility at two time points. On day one, the pulmonolo-
gist and research nurse screen the patient for eligibility
according to the inclusion and exclusion criteria listed
in table 1. On day 1 patients are considered eligible for
potential early discharge if they meet the following
inclusion criteria: aged 40 or over, competent, diagnosed
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Figure 1 Study design.
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with at least COPD GOLD stage 1 (post-bronchodilator
FEV1/FVC < 70% [3]) and a smoking history of mini-
mally 10 pack years (PY), hospitalised with a moderate
to severe exacerbation and finally, completed informed
consent on day three of admission. Patients are excluded
if they meet any of the following exclusion criteria:
major uncontrolled comorbidity, mental disability, active
alcohol- or drug abuse, inability to understand the pro-
gram, living outside the region of the participating
home care organisation, indication for admission to the
intensive care unit or non-invasive ventilation and insuf-
ficient availability of informal care at home.
On day 1, all patients considered eligible for potential
early discharge are invited to participate in the con-
trolled clinical trial in which they either continue their
hospital admission or are discharged early to home care.
These patients are informed that, if they fulfil the in-
and exclusion criteria and are still willing to participate
on day 3, they will be randomised on day 3 and dis-
charged on day 4. For patients admitted before 12:00
pm, the day of admission is considered as day 1, other-
wise, the following day is considered as day 1.
Patients must have signed the informed consent form
before randomisation on day 3, which means they have
three days to decide whether they want to participate in
the trial or not. This procedure is possible because the
treatment in the first three days is not different from
that of patients not participating in the trial. Data col-
lected before the third day of admission will be
destroyed if the patient does not give informed consent
on that day. This procedure has been approved by the
ethics committee.
Patients who refuse to participate in the trial are
invited to participate only in the discrete choice
experiment study without participating in the RCT.
These patients are contacted by telephone one month
after admission and asked to give informed consent for
this part of the study. This informed consent form is
different from the form that is used in the RCT.
Randomisation procedure
On the third day of admission clinical stability is
assessed in order to determine whether patients can be
randomised. This design for randomisation is adapted
from the Spanish study performed by Diaz et al. [21]
although the criteria for clinical stability were adapted
to represent the current practice in the participating
hospitals and because of the difference in treatment
package patients receive at home. Patients need to meet
the following criteria to be randomised: 1 acceptable
general health defined as decrease of physical com-
plaints, non dependency of therapies that can not be
given at home and being able to visit the toilet indepen-
dently; 2 normal or moderately increased blood sugar
levels, defined as ≤ 15 mmol/L or ≥ 15 mmol/L while
the patient is capable to regulate blood sugars indepen-
dently at home; and respiratory complaints of dyspnoea,
wheezing and rhonchi must have decreased in compari-
son with day one of admission. A special symptoms
scoring list adapted from the one used by Ojoo et al
[24] is used for this (see additional file 1: appendix 1).
This scoring chart scores the major exacerbation symp-
toms such as dyspnoea, coughing, mucus production
and colour and oedema. By scoring these symptoms
daily, improvement or deterioration in comparison with
the previous days becomes more visual and supports the
pulmonologist when applying the randomisation criteria
to the patient.
Table 1 Inclusion and exclusion criteria
Inclusion criteria:
Age 40 years and over
Competent
Diagnosed with at least COPD GOLD I and 10 Pack Years of smoking or grounded susceptibility for COPD
Hospitalised with COPD exacerbation




Active alcohol abuse and/or drug abuse
Inability to understand the program
Living outside care region of the home care organisation
Indication for admission to intensive care unit or non invasive ventilation
Insufficient availability of informal care at home
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Randomisation is performed on a 1:1 scale using a
computer-generated randomisation list that is placed in
sealed envelopes containing the allocation sequence of
the two treatment groups. Randomisation is performed
per participating location of the hospitals. We chose this
procedure to ensure all participating hospitals have a
similar proportion of patients in the intervention group
and patients in the control group and that the burden
for each participating home care organisations is similar.
Furthermore, a block size of 6 is applied to create equal
numbers in both groups.
The treatment protocol for the following four days is
started after randomisation and for the intervention
group the process of discharge planning is started.
Treatment protocol day 1-3 and day 4-7
The treatment protocol during the seven days of super-
vised treatment can be divided in the treatment before
randomisation and the treatment after randomisation.
During the first three days of the treatment all patients
receive usual care. The pharmacological part of this treat-
ment consists of systemic corticosteroids (10 days in total,
first 3 days 50 mg of oral or intravenous prednisolone or
other corticosteroid with an equivalent dose, following
7 days of 30 mg oral prednisolone or other corticosteroid
with an equivalent dose), nebulised bronchodilators (ipra-
tropium 500 μg/salbutamol 2.5 mg, 4-6 times per day),
sub cutaneous thrombosis prophylaxis, stomach protec-
tion - because of the high dosage of corticosteroids - and,
if necessary, oxygen therapy. Antibiotics are prescribed if
patients meet any of the following criteria: increase of the
amount of mucus, mucus purulence or CRP > 50 for
which no other cause can be determined. First choice of
antibiotics is co-amoxiclav. However, if previous mucus
cultures show sensitivity for different antibiotics, or
patients are allergic, different antibiotics can be prescribed.
Antibiotics are prescribed for at least 7 days.
Non-pharmacologic usual care consists of physiother-
apy for all patients and dietary advice upon indication
[39]. The physiotherapist instructs the patient in breath-
ing and coughing techniques and reactivation. A stan-
dardised (additional) written instruction was developed
ensuring identical instruction in the participating hospi-
tals. Dietary advice is indicated in case of a Body Mass
Index ≤ 21 or 10% unintended weight loss in the six
months prior to admission [39].
After randomisation systemic corticosteroids are con-
tinued and patients start with pressure metered dose
inhaled medication via spacer (at least an b2-antagonist
or anticolinergic with inhaled glucocorticosteroid).
Patients receive inhalation instruction on the day before
starting with these inhalations. Patients already using
nebulised inhalation medication prior to admission, may
continue this after randomisation.
The physiotherapist instructs patients to follow the
written instructions at home and dietary consultation is
continued as in usual care and at the dietician’s
judgement.
On the fourth day of admission the intervention group
is transferred home and undergoes the early assisted dis-
charge intervention. The control group remains hospita-
lised and receives usual care in hospital.
In both groups, patient recovery progress is monitored
daily using the translated and adapted exacerbation
symptom scoring chart.
Early assisted discharge intervention
Patients randomised into the early assisted discharge
group are transferred home on day four of admission.
The previously described treatment is continued at
home and supervised by nurses. These nurses have daily
contact with the patient for four consecutive days. Main
objective of the supervision of the home treatment is
the observation of the patient’s recovery and providing
counselling and reassurance to the patient and the pri-
mary informal caregiver. The nurses also address medi-
cation compliance and inhalation techniques, provide
support in applying breathing- and coughing techniques
and, if applicable, provide support in adhering to dietary
advices. If necessary patients, can be supported in their
daily life activities (e.g. washing and dressing) by the
home care organisation. During the four days of home
treatment, the emphasis lies on the recovery of the
exacerbation. Secondary objectives like disease manage-
ment and smoking cessation are addressed during the
first follow up moment one month after randomisation.
General practitioners are informed about patients’ par-
ticipation in the trial but are not directly involved in
these patients’ home care. In cases of deterioration of
the patient, the patient is discussed with the treating
hospital pulmonologist and if necessary the patient is
readmitted to the hospital. Patients can contact the hos-
pital 24 hours a day, 7 days a week with questions or in
cases of emergency.
Follow up visits
For both treatment groups two follow up visits at the
outpatient clinic are scheduled at one month and three
months after randomisation. During these visits patients
are seen by their own pulmonologist and a respiratory
nurse. The visits to the pulmonologist are as in usual
care, the visits to the respiratory nurse have a twofold
purpose. Firstly, these visits focus on the different aspects
of disease management. It is at the discretion of the
respiratory nurse which aspects need to be addressed in
each specific patient. Secondly, these visits are used to
collect, dispense and administer the questionnaires and
cost diaries. Additional visits can be planned at the
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discretion of the pulmonologist (e.g. for additional test-
ing) but do not fall under the study protocol. At the
three month follow up visit lung function testing and a
six minute walking distance test are performed as well.
Data collection
Data are collected on five time points: on the first day of
admission (T0), on the third day of admission (randomi-
sation, T1), at the end of the supervised treatment (day
7, T2) and one month (T3) and three months after ran-
domisation (T4).
We use self-administered questionnaires and cost dia-
ries to obtain data. The questionnaires are administered
when supervision is available. Cost diaries are supplied
at two time points (T2 and T3) for the up coming per-
iod, collected at the end of each follow up period and if
necessary completed under supervision.
Effect evaluation
Table 2 provides an overview of the measures of the
effect evaluation and the economic evaluation, and at
which time point the measurements are performed.
Primary outcome measurements
Primary outcome measure in this study is the effective-
ness of early assisted discharge compared to usual care
expressed by the change on the Clinical COPD Ques-
tionnaire (CCQ) [38] between the third day of admission
(T1) and the last day of supervised treatment (T2 = day
7). The CCQ is a disease specific, ten-item questionnaire
that calculates an overall score and three domain scores:
symptoms, functional state and emotional state. All
items are scored on a seven point scale with 0 repre-
senting the best possible score and 6 representing the
worst possible score [38]. In this study the version with
a 24-hour recall period is used, reflecting the health sta-
tus of the past 24 hours. The CCQ is responsive to
change [38] and a study in patients admitted to the hos-
pital with an acute exacerbation of COPD, indicated
that the minimal clinical important difference (MCID)
of the CCQ is 0.4 [40].
Secondary outcome measurements
Main secondary outcome measurement of the study is
the cost-effectiveness. This will be discussed in the eco-
nomic evaluation section. The following other secondary
measurements will be performed. These correspond
with the secondary research questions from the last
paragraph of the introduction:
1. Long-term effectiveness, measured with the CCQ
change over the time points from day 1 to the end
of the follow-up period (T4).
2. Number of treatment failures.
3. Number of readmissions to hospital and time to
readmission during the three months follow-up
period.
4. Mortality and time to death during the three
months follow-up.
5. Generic health related quality of life, measured
with the EuroQol (EQ-5D) 5D [41]. The EQ-5D will
also be used to calculate quality adjusted life year
(QALYs), discussed in the economic evaluation
section.
6. Effects on primary informal caregiver burden mea-
sured by the Caregiver Strain Index [42].
7. Patient and primary informal caregiver satisfaction
with the program. We use a translated version of the
satisfaction questionnaire used by Ojoo et al. [24]
and extended it with additional questions.
Patient characteristics
Patients are characterised using the following variables:
demographic factors (age, gender, socioeconomic status
measured through level of education and income),
smoking, Body Mass Index, living situation, comorbidity
measured with the Charlson Comorbidity Index (CCI)
[43], Coping Style measured with the Utrecht Coping
List [44], medical treatment at home prior to the
Table 2 Overview of measurements per time point
Measurement T0 T1 T2 T3 T4
Demographic characteristics x
Smoking x
Body Mass Index x
Living situation x
Comorbidity x
Coping style (UCL) x
Medical treatment prior to admission x
Exacerbation severity x
Indication for admission x
Clinical COPD Questionnaire (CCQ) x x x x
EuroQol 5D (EQ-5D) x x x
Satisfaction
patient satisfaction x x
primary caregiver satisfaction x x




Cost diary x (IG) x x
Discrete Choice Experiment x
Lung function testing x
6 Minute Walking Distance x
T0 = baseline; T1 = randomisation; T2 = end of supervised treatment; T3 =
follow up 1; T4 = follow up 2; IG = intervention group only.
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admission, severity of the exacerbation, indication for
admission and finally severity of the disease are mea-
sured as well. In addition, severity of COPD is measured
three months after admission at the end of the follow
up period by performing lung function testing and a six
minute walking test.
Economic evaluation
In accordance with the broad international consensus
that economic evaluations should be conducted from a
societal perspective [45] this cost-effectiveness analysis
will include all costs, irrespective of who actually bears
them.
All direct health care and non-health care costs as
well as the costs of productivity losses of patient and
caregiver within the three months after randomisation
will be taken into account.
The following types of resource use will be recorded
to calculate direct health care costs: number and length
of hospital admissions and readmissions, total amount
of time of community nursing care (distinguished by
nurse grade), number of visits to the emergency depart-
ment, number of contacts with pulmonologist, other
specialist physicians, general practitioner, respiratory
nurse, dietician, physiotherapist, and social worker,
number of ambulance rides and medication use. These
will be recorded in cost diaries and obtained from hos-
pital records. Costs of organisational arrangements of
the early discharge scheme will also be included.
Direct non-health care costs primarily include paid
and unpaid household help, including the time spent by
the primary informal caregiver.
Indirect costs are costs of productivity losses. We
record the days a patient is absent from paid work. We
also ask informal caregivers to record the number of days
off work due to caring for the patient. Costs are calcu-
lated by multiplying the volume of resource use (such as
hospital days, physician visits, time spent by formal and
informal caregivers) by a price per unit that includes
total, not marginal costs.
In addition to the societal perspective, we will calcu-
late the costs from the financial hospital perspective, the
financial perspective of the organisation providing the
home care and the perspective of the health care sector.
This includes costs covered by the hospital budget, the
budget of the homecare organisation and the health care
sectors budget, respectively.
The principal health outcome measures in the eco-
nomic evaluation are the number of patients with a
clinically relevant improvement in CCQ between day
of randomisation and day 7, and between day of ran-
domisation and month 3, the change in CCQ score
between day of randomisation and day 7 and day of
randomisation and month 3, the number of QALYs
randomisation and the end of the three-month follow-
up period. The latter is calculated using the Dutch
EQ-5D tariff [46].
Health outcomes will be related to cost outcomes. If one
of the treatment options is more effective but also more
costly, results will be presented as an incremental cost-
effectiveness analysis: the additional cost per additional
unit of health gain, which is calculated as the difference in
mean costs between early discharge and usual inpatient
hospital care divided by the in mean health effects.
Data analysis
Data analysis will be performed according to the intention
to treat principle. Data from patients who die, quit partici-
pation or are otherwise lost to follow up will be included
in the analysis up until the point of drop out. Missing
observations will be imputed or weighted appropriately.
All primary and secondary outcome measurements
will be analysed using analysis of covariance. In order to
control for dependency between the repeated measure-
ments within one patient, and for the dependency
between patients from the same hospital, multilevel ana-
lyses will be performed as well. We set the significance
level at a = 0.05.
Primary outcome measure
The changes on the primary outcome measurement, the
CCQ, will be analysed with the repeated measurements
ANOVA technique. The dependent variable is the
change in CCQ score from baseline (T1) to the end of
the supervised treatment (T2). Treatment group is con-
sidered as independent variable and baseline CCQ score
(T1) and centre of treatment are considered as covari-
ates. Age, gender and severity of the disease will also be
included in the model as covariates. If necessary, other
covariates will be included in the model.
Secondary outcomes measurements
All time-to-event outcomes (i.e. time to readmission and
time to death) will be analysed using Kaplan-Meier curves
and Cox Proportional Hazards regression model. Event
rates (i.e. treatment failures, readmission rates and mortal-
ity rates) will be analysed using an appropriate model for
count data (e.g. poisson regression or binomial regression)
Differences in outcomes defined as the mean change
from baseline (e.g. long-term effectiveness, primary
informal caregiver burden, patient- and primary infor-
mal caregiver satisfaction and quality of life) will be ana-
lysed using repeated measurements ANOVA.
Patient- and caregiver preference for place of treat-
ment will be analysed using a logistic regression model.
Cost-effectiveness
In order to derive the total utility experienced over the
course of the investigation, the number of QALYs per
patient will be calculated as the area under the utility
curve.
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Uncertainty around the estimates of costs and health
outcomes will be addressed by bootstrapping the data
with bias correction and acceleration (BCa) [47,48].
The 95% confidence interval around the difference in
mean costs and health outcomes will be determined by
taking the 2.5th percentile and the 97.5th percentile of
these bootstrap replications. The bootstrap replicates
will be plotted in cost-effectiveness planes (CE-planes).
A CE-plane is an x-y-diagram with the x-axis repre-
senting the difference in health outcome between the
treatment and usual care group and the y-axis repre-
senting the difference in costs. By plotting all bootstrap
replicates in this diagram the uncertainty around the
point estimates of the ICERs will be displayed [47].
The information from the CE-planes will be sum-
marised into cost-effectiveness acceptability curves,
which represent the likelihood that early assisted dis-
charge is the most cost-effective option at different
values of the maximum acceptable willingness to pay
(WTP) for a health outcome [48].
Sample Size calculation
Primary outcome is the change in the CCQ score
between baseline (day 3 of admission) and the end of
the supervised treatment (day 7).
Before the start of the study, a preliminary sample size
calculation for an independent samples t-test was per-
formed based on the results of a pilot study, where the
average CCQ decreased from 3.8 on the day of admis-
sion to 2.6 by the end of the supervised treatment The
standard deviation of that change was 1.04. With a
MCID of 0.4, the required Cohen’s effect size d would
be 0.385 [99]. For a risk of a type-I error of 5% (a =
0.05) and a risk of a type-II error 20% (1-b = 0.80), the
required sample size was 214.
However, primary outcome measure in this study is
the change in the CCQ score from the third day of
admission and the end of the supervised treatment (day
7), which is likely to have a stronger correlation with
the baseline score. Therefore, a new sample size calcula-
tion for ANCOVA was performed after 85 patients had
been treated, without breaking the randomisation code.
Taking into account the correlation between the base-
line score and the change (r = 0.288), as well as the
standard deviations measured in the trial (0.988 for the
intervention group and 0.922 for the control group), the
required effect size f is 0.22 and the sample size is 165.
Discrete Choice Experiment
Background
As part of the GO AHEAD trial we perform a discrete
choice experiment (DCE) to explore the preferences of
patients and their informal caregivers for different
treatment arrangements. The DCE provides quantitative
information on the relative importance of the character-
istics of the hospital treatment and the early assisted
discharge scheme and the rate at which patients are
willing to trade between them.
A DCE is a type of conjoint analysis used to deter-
mine individual preferences. In this study it involves
presenting respondents with a series of choices between
an early assisted discharge scenario and a usual hospital
care scenario. Each scenario is described in terms of
several characteristics, which are called attributes.
DCEs originate from mathematical psychology and
have been most widely applied in market research to
determine consumer preferences for goods and services
and investigate the relative importance of the character-
istics of these goods and services [49,50].
Design
A review of literature and conversations with patients
and pulmonologists have lead to the selection of seven
attributes with two or three levels each for the home
treatment options, while the hospital option is kept con-
stant and is not described by attributes. The attributes
for the home treatments are: type of nurse (generic or
respiratory), number of home visits (1, 2 or 3 per day),
copayment (€0, €50 or €100), risk of readmission to hos-
pital within treatment period (1%, 5% or 10%), whom to
contact in case of emergency (general practitioner or
pulmonary ward in the hospital), number of hours of
informal care (1, 3 or 5 hours per day), number of dif-
ferent nurses visiting the patient (1-2 or more than two).
The questionnaire consists of 14 choice scenarios, two
of which have a ‘right answer’ and aimed at testing if
the respondent understands the task. There are three
versions of the questionnaire, which add up to a D-opti-
mal design of 36 different scenarios. Each respondent is
asked to complete one version of the questionnaire.
In each scenario respondents indicate a preference for
one of two home treatment options or the complete
hospital treatment. Respondents who initially choose the
hospital option, are subsequently asked to make a choice
between the two home treatments. By using this forced
choice question, we ascertain that all respondents pro-
vide information about their preferences for attributes
of the home treatment.
Data analysis
Depending on the choice pattern of the respondents, the
data will be analysed using conditional logit model with
alternative-specific constants, a random parameter mul-
tinomial logit model (i.e. a mixed logit model) or a mul-
tilevel latent class conditional logit model, all with and
without interaction effects.
This analysis results in a regression coefficient for
each level of the attributes. The estimated coefficients
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allow conclusions to be made about the relative impor-
tance of the attributes and possible trade-offs between
them.
Furthermore, we will test whether the patients who
were assigned to the early assisted discharge scheme
have different preferences for various characteristics of
the care delivery than patients who were assigned to the
conventional inpatient hospital care.
Finally, we will test for differences in preferences
between patients, their informal and formal caregivers.
Discussion
We presented the protocol of the GO AHEAD study,
which assesses the effectiveness and cost-effectiveness of
an early assisted discharge intervention for patients
admitted to the hospital for a COPD exacerbation. It is
a multi-centre RCT comparing the early assisted dis-
charge intervention with usual care in the hospital.
Despite research on the effectiveness of early assisted
discharge for COPD exacerbations, several aspects of
these hospital at home schemes remain unclear. This
study will provide not only information on the effective-
ness and cost-effectiveness, but also on which aspects of
the intervention are important for patients to make a
certain choice (DCE) and secondary outcome measure-
ments, namely effects on quality of life, effects on pri-
mary caregiver burden and patient and primary
caregiver satisfaction.
There are several critical success factors to be
mentioned.
In the past two decades average length of hospital
stay, for acute care of all conditions, has already
decreased internationally from approximately 9 days to
6 days [51]. Average length of stay for COPD exacerba-
tions follows these trends, with changes from approxi-
mately 8.5 days to 6.5 days [11,37,52]. Although this
trend has occurred in the Netherlands as well, average
length of hospital stay for COPD patients is still 10.5
days [53]. With the projected increasing prevalence of
COPD, especially for women, in the following years, this
leaves room for interventions that reduce length of stay.
Prolonged hospital stay is associated with the presence
of comorbidities [54], continuation of conservative ther-
apy (e.g. therapies that can only be given in hospital or
pulmonologists wish to observe stable patients) [37] and
complex discharge planning that requires additional
home care arrangements) [37,52] among others. More-
over, comorbidities are more present in patients with
more severe COPD [55], and most patients hospitalised
have COPD stages III or more [52,56]. This might sug-
gest that the Dutch hospitalised population is different
from that in the United Kingdom. However, the national
UK audit from 2008 [56] showed that severity of the
disease of patients admitted to the hospital has not
changed between 2003 and 2008 (median FEV1 = 38%
of predicted value, GOLD stage III) and 77% of all
patients admitted to hospital have one or more
comorbidities.
Early assisted discharge also anticipates for the need
for social work involvement during hospitalisation. In
the early assisted discharge scheme care at home is
arranged for a certain number of days and patients are
closely monitored at home. Because of the presence of
nurses at home, the possible need for prolonged or
extended home care is quickly identified. Arrangements
can be made more easily because patients are already in
the system of the home care organisation.
In the United Kingdom, early assisted discharge for
COPD exacerbations is more common in hospitals that
are characterised by greater number of hospital beds,
higher numbers of hospital admissions and the presence
of respiratory nurses [15]. The Dutch hospitals are of
similar as or larger than those in the United Kingdom
[51]. The number of admissions is high (11,6 per 10.000
population in 2007 [67]) and respiratory nurses have an
important role in patient care. The Dutch health care
systems also has a large network of primary care organi-
sations that deliver home care that is easily accessible
for the population. Therefore the use of generic com-
munity nurses in the early assisted discharge scheme is
possible.
Despite similarities between the British and Dutch
health care system, organisational and financial differ-
ences between these countries exist and results from
studies performed in one country, with its own charac-
teristics, can not simply be translated to and implemen-
ted in other countries. Similarities and differences
should be studied more intensively and taken into
account before implementing early assisted discharge in
the Dutch health care system. Possible boundary for
implementation in the Netherlands are the different
reimbursement systems and budgets of hospital care
and home care. An integrated financing structure may
facilitate the implementation in the health care system.
In this trial supervision of the treatment at home is
either performed by community based, generic nurses
or hospital resourced specialised respiratory nurses
(nurse practitioners). The use of hospital resourced spe-
cialised respiratory nurses is the most frequently
described and studied form of supervision at home.
Using generic community nurses, who are more avail-
able and less costly, could enable the development of
more hospital at home services. In this study both stra-
tegies for early assisted discharge (hospital resources or
community based) and the different professionals
involved in home care (generic nurses or specialised
respiratory nurses) are being used. When sample sizes
of both groups allow it, this study may provide more
Utens et al. BMC Public Health 2010, 10:618
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insight in which model for early assisted discharge is
more preferable.
Compared to commonly applied measures of satisfac-
tion, a DCE quantifies the relative importance of the
characteristics and levels. It assesses the trade-offs that
respondents make and provides an estimate of the over-
all value of early assisted discharge treatments and the
usual inpatient hospital care option.
Because common satisfaction questionnaires do not
quantify the relative importance of attributes and levels,
it is likely that patient preferences are not represented
correctly in organising the process of care delivery. This
may lead to suboptimal decision-making and may
impair the acceptance of early assisted discharge.
To summarise, in this contribution we presented the
research protocol of a multi-centre RCT studying the
effectiveness and cost-effectiveness of an early assisted
discharge scheme for COPD exacerbations in the
Netherlands.
Additional material
Appendix 1: Exacerbation symptom scoring chart. Scoring chart for
exacerbation symptoms that shows the course of symptoms during the
7 days treatment.
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